APA

Shek F. H., Luo R., Lam B. Y. H., Sung W. K., Lam T., Luk J. M., Leung M. S., Chan K. T., Wang H. K., Chan C. M., Poon R. T. & Lee N. P. (20180702). Serine peptidase inhibitor Kazal type 1 (SPINK1) as novel downstream effector of the cadherin-17/β-catenin axis in hepatocellular carcinoma. : Cellular oncology (Dordrecht, Netherlands).

Chicago

Shek Felix H, Luo Ruibang, Lam Brian Y H, Sung Wing Kin, Lam Tak-Wah, Luk John M, Leung Ming Sum, Chan Kin Tak, Wang Hector K, Chan Chung Man, Poon Ronnie T and Lee Nikki P. 20180702. Serine peptidase inhibitor Kazal type 1 (SPINK1) as novel downstream effector of the cadherin-17/β-catenin axis in hepatocellular carcinoma. : Cellular oncology (Dordrecht, Netherlands).

Harvard

Shek F. H., Luo R., Lam B. Y. H., Sung W. K., Lam T., Luk J. M., Leung M. S., Chan K. T., Wang H. K., Chan C. M., Poon R. T. and Lee N. P. (20180702). Serine peptidase inhibitor Kazal type 1 (SPINK1) as novel downstream effector of the cadherin-17/β-catenin axis in hepatocellular carcinoma. : Cellular oncology (Dordrecht, Netherlands).

MLA

Shek Felix H, Luo Ruibang, Lam Brian Y H, Sung Wing Kin, Lam Tak-Wah, Luk John M, Leung Ming Sum, Chan Kin Tak, Wang Hector K, Chan Chung Man, Poon Ronnie T and Lee Nikki P. Serine peptidase inhibitor Kazal type 1 (SPINK1) as novel downstream effector of the cadherin-17/β-catenin axis in hepatocellular carcinoma. : Cellular oncology (Dordrecht, Netherlands). 20180702.